Form 4: Sensei Biotherapeutics Director Acquires Stock Options

Kristian Humer, a director of Sensei Biotherapeutics, acquired stock options exercisable for 19,000 shares of common stock.

Summary

• On June 11, 2024, Kristian Humer, a director of Sensei Biotherapeutics, Inc., was granted stock options to purchase 19,000 shares of common stock.
• The exercise price of the options is $0.709 per share.
• The options vest in 12 equal monthly installments, becoming fully vested on June 11, 2025, subject to continuous service with the Issuer.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
• The expiration date for the options is June 10, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed positively as it aligns director interests with shareholders. There are no red flags or negative indicators.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is typical for such grants, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like Iovance Biotherapeutics and Adaptimmune Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance contributes to the company's success.
• The vesting schedule incentivizes the director to remain with the company, providing stability.

Key Dates

Keywords

stock options, Sensei Biotherapeutics, director, SNSE, Form 4, beneficial ownership, Kristian Humer